speb/financial-data huggingface dataset:
DRMA balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 7301222.00
DRMA balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 7301222.00
DRMA income_statement (quarterly, 2025-03-31) — Total Expenses: 2339803.00
DRMA balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 2703785.00
DRMA balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 0.00
DRMA balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 0.00
DRMA income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -2339803.00
DRMA balance_sheet (quarterly, 2025-03-31) — Working Capital: 7301222.00
DRMA income_statement (quarterly, 2025-06-30) — +Operating Expense: 1772731.00
DRMA income_statement (quarterly, 2025-06-30) — +Total Revenue: 0.00
DRMA balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 413687.00
DRMA balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 75294206.00
DRMA income_statement (quarterly, 2025-06-30) — Basic Average Shares: 1026506.00
DRMA income_statement (quarterly, 2025-06-30) — Basic EPS: -1.66
DRMA cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 9719268.00
DRMA balance_sheet (quarterly, 2025-06-30) — Capital Stock: 64.00
DRMA balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 6480930.00
DRMA balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 6480930.00
DRMA cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -547857.00
DRMA cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -2690481.00
DRMA cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -458880.00
DRMA cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: -695894.00
DRMA cash_flow (quarterly, 2025-06-30) — Change In Payable: -458880.00
DRMA cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -1154774.00
DRMA cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 126153.00
DRMA cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -1028621.00
DRMA cash_flow (quarterly, 2025-06-30) — Changes In Cash: -3238338.00
DRMA balance_sheet (quarterly, 2025-06-30) — Common Stock: 64.00
DRMA balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 5614251.00
DRMA cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: -547857.00
DRMA balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 121875.00
DRMA balance_sheet (quarterly, 2025-06-30) — Current Assets: 6640516.00
DRMA balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 1026265.00
DRMA income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 1026506.00
DRMA income_statement (quarterly, 2025-06-30) — Diluted EPS: -1.66
DRMA income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -1701093.00
DRMA income_statement (quarterly, 2025-06-30) — EBIT: -1772731.00
DRMA income_statement (quarterly, 2025-06-30) — EBITDA: -1772731.00
DRMA cash_flow (quarterly, 2025-06-30) — End Cash Position: 6480930.00
DRMA cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -547857.00
DRMA cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -2690481.00
DRMA income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 1154896.00
DRMA income_statement (quarterly, 2025-06-30) — Interest Income: 71638.00
DRMA income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 71638.00
DRMA balance_sheet (quarterly, 2025-06-30) — Invested Capital: 5614251.00
DRMA cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: -547857.00
DRMA cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -547857.00
DRMA income_statement (quarterly, 2025-06-30) — Net Income: -1701093.00
DRMA income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -1701093.00
DRMA income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -1701093.00
DRMA income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -1701093.00
DRMA income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -1701093.00
DRMA cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -1701093.00
DRMA income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -1701093.00
DRMA income_statement (quarterly, 2025-06-30) — Net Interest Income: 71638.00
DRMA income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 71638.00
DRMA cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: 0.00
DRMA balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 5614251.00
DRMA income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -1772731.00
DRMA income_statement (quarterly, 2025-06-30) — Normalized Income: -1701093.00
DRMA cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -2690481.00
DRMA income_statement (quarterly, 2025-06-30) — Operating Income: -1772731.00
DRMA income_statement (quarterly, 2025-06-30) — Operating Revenue: 0.00
DRMA balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 637757.00
DRMA balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 83532.00
DRMA income_statement (quarterly, 2025-06-30) — Other Gand A: 1154896.00
DRMA balance_sheet (quarterly, 2025-06-30) — Payables: 413687.00
DRMA balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 535562.00
DRMA balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 490703.00
DRMA balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 76054.00
DRMA income_statement (quarterly, 2025-06-30) — Pretax Income: -1701093.00
DRMA cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 0.00
DRMA income_statement (quarterly, 2025-06-30) — Research And Development: 617835.00
DRMA balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -69680019.00
DRMA income_statement (quarterly, 2025-06-30) — Selling General And Administration: 1154896.00
DRMA balance_sheet (quarterly, 2025-06-30) — Share Issued: 637757.00
DRMA cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 39233.00
DRMA balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 5614251.00
DRMA balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 5614251.00
DRMA income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
DRMA income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
DRMA balance_sheet (quarterly, 2025-06-30) — Total Assets: 6640516.00
DRMA balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 5614251.00
DRMA balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 5614251.00
DRMA income_statement (quarterly, 2025-06-30) — Total Expenses: 1772731.00
DRMA balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 1026265.00
DRMA balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 0.00
DRMA balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 0.00
DRMA income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -1772731.00
DRMA balance_sheet (quarterly, 2025-06-30) — Working Capital: 5614251.00
DRMA income_statement (quarterly, 2025-09-30) — +Operating Expense: 1760671.00
DRMA income_statement (quarterly, 2025-09-30) — +Total Revenue: 0.00
DRMA balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 453427.00
DRMA balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 75332026.00
DRMA income_statement (quarterly, 2025-09-30) — Basic Average Shares: 1026457.00
DRMA income_statement (quarterly, 2025-09-30) — Basic EPS: -1.65
DRMA cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 6480930.00
DRMA balance_sheet (quarterly, 2025-09-30) — Capital Stock: 84.00
DRMA balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 4664127.00
DRMA balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 4664127.00
DRMA cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -12988.00
DRMA cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -1803815.00
DRMA cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 52727.00
DRMA cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 45303.00
DRMA cash_flow (quarterly, 2025-09-30) — Change In Payable: 52727.00
DRMA cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 98030.00
DRMA cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -247697.00
DRMA cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -149667.00
DRMA cash_flow (quarterly, 2025-09-30) — Changes In Cash: -1816803.00
DRMA balance_sheet (quarterly, 2025-09-30) — Common Stock: 84.00
DRMA balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 3960102.00
DRMA cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: -12621.00
DRMA cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -367.00
DRMA balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 63737.00
DRMA balance_sheet (quarterly, 2025-09-30) — Current Assets: 5071410.00
DRMA balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 1111308.00
DRMA income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 1026457.00
DRMA income_statement (quarterly, 2025-09-30) — Diluted EPS: -1.65
DRMA income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -1691989.00
DRMA income_statement (quarterly, 2025-09-30) — EBIT: -1760671.00
DRMA income_statement (quarterly, 2025-09-30) — EBITDA: -1760671.00
DRMA cash_flow (quarterly, 2025-09-30) — End Cash Position: 4664127.00
DRMA cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -12988.00
DRMA cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -1803815.00
DRMA income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 783344.00
DRMA cash_flow (quarterly, 2025-09-30) — Income Tax Paid Supplemental Data: 0.00
DRMA income_statement (quarterly, 2025-09-30) — Interest Income: 68682.00
DRMA income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 68682.00
DRMA balance_sheet (quarterly, 2025-09-30) — Invested Capital: 3960102.00
DRMA cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: -12621.00
DRMA cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -12988.00
DRMA income_statement (quarterly, 2025-09-30) — Net Income: -1691989.00
DRMA income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -1691989.00
DRMA income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -1691989.00
DRMA income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -1691989.00
DRMA income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -1691989.00
DRMA cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -1691989.00
DRMA income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -1691989.00
DRMA income_statement (quarterly, 2025-09-30) — Net Interest Income: 68682.00
DRMA income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 68682.00
DRMA cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: 0.00
DRMA balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 3960102.00
DRMA income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -1760671.00
DRMA income_statement (quarterly, 2025-09-30) — Normalized Income: -1691989.00
DRMA cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -1803815.00
DRMA income_statement (quarterly, 2025-09-30) — Operating Income: -1760671.00
DRMA income_statement (quarterly, 2025-09-30) — Operating Revenue: 0.00
DRMA balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 844457.00
DRMA balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 45826.00
DRMA income_statement (quarterly, 2025-09-30) — Other Gand A: 475503.00
DRMA balance_sheet (quarterly, 2025-09-30) — Payables: 453427.00
DRMA balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 517164.00
DRMA balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 594144.00
DRMA balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 0.00
DRMA balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 361457.00
DRMA income_statement (quarterly, 2025-09-30) — Pretax Income: -1691989.00
DRMA cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 0.00
DRMA cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -367.00
DRMA income_statement (quarterly, 2025-09-30) — Research And Development: 504387.00
DRMA balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -71372008.00
DRMA income_statement (quarterly, 2025-09-30) — Salaries And Wages: 307841.00
DRMA income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 472940.00
DRMA income_statement (quarterly, 2025-09-30) — Selling General And Administration: 1256284.00
DRMA balance_sheet (quarterly, 2025-09-30) — Share Issued: 844457.00
DRMA cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 37841.00
DRMA balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 3960102.00
DRMA balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 3960102.00
DRMA income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
DRMA income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
DRMA balance_sheet (quarterly, 2025-09-30) — Total Assets: 5071410.00
DRMA balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 3960102.00
DRMA balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 3960102.00
DRMA income_statement (quarterly, 2025-09-30) — Total Expenses: 1760671.00
DRMA balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 1111308.00
DRMA balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 0.00
DRMA balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 0.00
DRMA income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -1760671.00
DRMA balance_sheet (quarterly, 2025-09-30) — Working Capital: 3960102.00
DRMA income_statement (annual, 2025-12-31) — +Operating Expense: 7773598.00
DRMA income_statement (quarterly, 2025-12-31) — +Operating Expense: 1900393.00
DRMA income_statement (annual, 2025-12-31) — +Total Revenue: 0.00
DRMA income_statement (quarterly, 2025-12-31) — +Total Revenue: 0.00
DRMA balance_sheet (annual, 2025-12-31) — Accounts Payable: 460811.00
DRMA balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 460811.00
DRMA balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 79457010.00
DRMA balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 79457010.00
DRMA income_statement (annual, 2025-12-31) — Basic Average Shares: 926192.00
DRMA income_statement (annual, 2025-12-31) — Basic EPS: -8.16
DRMA cash_flow (annual, 2025-12-31) — Beginning Cash Position: 3161570.00
DRMA cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 4664127.00
DRMA balance_sheet (annual, 2025-12-31) — Capital Stock: 266.00
DRMA balance_sheet (quarterly, 2025-12-31) — Capital Stock: 266.00
DRMA balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 7521978.00
DRMA balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 7521978.00
DRMA balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 7521978.00
DRMA balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 7521978.00
DRMA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 12117967.00
DRMA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 4187048.00
DRMA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -7757559.00
DRMA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -1329197.00
DRMA cash_flow (annual, 2025-12-31) — Change In Account Payable: -388056.00
DRMA cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -83967.00
DRMA cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 14852.00
DRMA cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 521754.00
DRMA cash_flow (annual, 2025-12-31) — Change In Payable: -388056.00
DRMA cash_flow (quarterly, 2025-12-31) — Change In Payable: -83967.00
DRMA cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: -373204.00
DRMA cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 437787.00
DRMA cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: 30470.00
DRMA cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 65435.00
DRMA cash_flow (annual, 2025-12-31) — Change In Working Capital: -342734.00
DRMA cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 503222.00
DRMA cash_flow (annual, 2025-12-31) — Changes In Cash: 4360408.00
DRMA cash_flow (quarterly, 2025-12-31) — Changes In Cash: 2857851.00
DRMA balance_sheet (annual, 2025-12-31) — Common Stock: 266.00
DRMA balance_sheet (quarterly, 2025-12-31) — Common Stock: 266.00
DRMA balance_sheet (annual, 2025-12-31) — Common Stock Equity: 6223380.00
DRMA balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 6223380.00
DRMA cash_flow (annual, 2025-12-31) — Common Stock Issuance: 12167852.00
DRMA cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 4187048.00
DRMA cash_flow (annual, 2025-12-31) — Common Stock Payments: -367.00
DRMA cash_flow (quarterly, 2025-12-31) — Common Stock Payments: 0.00
DRMA balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 200182.00
DRMA balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 200182.00
DRMA balance_sheet (annual, 2025-12-31) — Current Assets: 7863826.00
DRMA balance_sheet (quarterly, 2025-12-31) — Current Assets: 7863826.00
DRMA balance_sheet (annual, 2025-12-31) — Current Liabilities: 1640446.00
DRMA balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 1640446.00
DRMA income_statement (annual, 2025-12-31) — Diluted Average Shares: 926192.00
DRMA income_statement (annual, 2025-12-31) — Diluted EPS: -8.16
DRMA income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -7558557.00
DRMA income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -1861888.00
DRMA income_statement (annual, 2025-12-31) — EBIT: -7773598.00
DRMA income_statement (quarterly, 2025-12-31) — EBIT: -1900393.00
DRMA income_statement (annual, 2025-12-31) — EBITDA: -7773598.00
DRMA income_statement (quarterly, 2025-12-31) — EBITDA: -1900393.00
DRMA cash_flow (annual, 2025-12-31) — End Cash Position: 7521978.00
DRMA cash_flow (quarterly, 2025-12-31) — End Cash Position: 7521978.00
DRMA cash_flow (annual, 2025-12-31) — Financing Cash Flow: 12117967.00
DRMA cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 4187048.00
DRMA cash_flow (annual, 2025-12-31) — Free Cash Flow: -7757559.00
DRMA cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -1329197.00
DRMA cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 950.00
DRMA cash_flow (quarterly, 2025-12-31) — Income Tax Paid Supplemental Data: 0.00
DRMA income_statement (annual, 2025-12-31) — Interest Income: 215041.00
DRMA income_statement (quarterly, 2025-12-31) — Interest Income: 38505.00
DRMA income_statement (annual, 2025-12-31) — Interest Income Non Operating: 215041.00
DRMA income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 38505.00
DRMA balance_sheet (annual, 2025-12-31) — Invested Capital: 6223380.00
DRMA balance_sheet (quarterly, 2025-12-31) — Invested Capital: 6223380.00
DRMA cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 12167852.00
DRMA cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 4187048.00
DRMA cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 12167485.00
DRMA cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 4187048.00
DRMA income_statement (annual, 2025-12-31) — Net Income: -7558557.00
DRMA income_statement (quarterly, 2025-12-31) — Net Income: -1861888.00
DRMA income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -7558557.00
DRMA income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -1861888.00
DRMA income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -7558557.00
DRMA income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -1861888.00
DRMA income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -7558557.00
DRMA income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -1861888.00
DRMA income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -7558557.00
DRMA income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -1861888.00
DRMA cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -7558557.00
DRMA cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -1861888.00
DRMA income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -7558557.00
DRMA income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -1861888.00
DRMA income_statement (annual, 2025-12-31) — Net Interest Income: 215041.00
DRMA income_statement (quarterly, 2025-12-31) — Net Interest Income: 38505.00
DRMA income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 215041.00
DRMA income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 38505.00
DRMA cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -50495.00
DRMA cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: 0.00
DRMA balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 6223380.00
DRMA balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 6223380.00
DRMA income_statement (annual, 2025-12-31) — Normalized EBITDA: -7773598.00
DRMA income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -1900393.00
DRMA income_statement (annual, 2025-12-31) — Normalized Income: -7558557.00
DRMA income_statement (quarterly, 2025-12-31) — Normalized Income: -1861888.00
DRMA cash_flow (annual, 2025-12-31) — Operating Cash Flow: -7757559.00
DRMA cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -1329197.00
DRMA income_statement (annual, 2025-12-31) — Operating Income: -7773598.00
DRMA income_statement (quarterly, 2025-12-31) — Operating Income: -1900393.00
DRMA income_statement (annual, 2025-12-31) — Operating Revenue: 0.00
DRMA income_statement (quarterly, 2025-12-31) — Operating Revenue: 0.00
DRMA balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 2660110.00
DRMA balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 2660110.00
DRMA balance_sheet (annual, 2025-12-31) — Payables: 460811.00
DRMA balance_sheet (quarterly, 2025-12-31) — Payables: 460811.00
DRMA balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 660993.00
DRMA balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 660993.00
DRMA balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 979453.00
DRMA balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 979453.00
DRMA balance_sheet (annual, 2025-12-31) — Prepaid Assets: 341848.00
DRMA balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 341848.00
DRMA income_statement (annual, 2025-12-31) — Pretax Income: -7558557.00
DRMA income_statement (quarterly, 2025-12-31) — Pretax Income: -1861888.00
DRMA cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 977.00
DRMA cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 0.00
DRMA cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -367.00
DRMA cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: 0.00
DRMA income_statement (annual, 2025-12-31) — Research And Development: 2929983.00
DRMA income_statement (quarterly, 2025-12-31) — Research And Development: 526620.00
DRMA balance_sheet (annual, 2025-12-31) — Retained Earnings: -73233896.00
DRMA balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -73233896.00
DRMA income_statement (annual, 2025-12-31) — Selling General And Administration: 4843615.00
DRMA income_statement (quarterly, 2025-12-31) — Selling General And Administration: 1373773.00
DRMA balance_sheet (annual, 2025-12-31) — Share Issued: 2660110.00
DRMA balance_sheet (quarterly, 2025-12-31) — Share Issued: 2660110.00
DRMA cash_flow (annual, 2025-12-31) — Stock Based Compensation: 143732.00
DRMA cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 29469.00
DRMA balance_sheet (annual, 2025-12-31) — Stockholders Equity: 6223380.00
DRMA balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 6223380.00
DRMA balance_sheet (annual, 2025-12-31) — Tangible Book Value: 6223380.00
DRMA balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 6223380.00
DRMA income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
DRMA income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
DRMA income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.00
DRMA income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
DRMA balance_sheet (annual, 2025-12-31) — Total Assets: 7863826.00
DRMA balance_sheet (quarterly, 2025-12-31) — Total Assets: 7863826.00
DRMA balance_sheet (annual, 2025-12-31) — Total Capitalization: 6223380.00
DRMA balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 6223380.00
DRMA balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 6223380.00
DRMA balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 6223380.00
DRMA income_statement (annual, 2025-12-31) — Total Expenses: 7773598.00
DRMA income_statement (quarterly, 2025-12-31) — Total Expenses: 1900393.00
DRMA balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 1640446.00
DRMA balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 1640446.00
DRMA balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 0.00
DRMA balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 0.00
DRMA balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
DRMA balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
DRMA income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -7773598.00
DRMA income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -1900393.00
DRMA balance_sheet (annual, 2025-12-31) — Working Capital: 6223380.00
DRMA balance_sheet (quarterly, 2025-12-31) — Working Capital: 6223380.00
DRMA income_statement (quarterly, 2026-03-31) — +Operating Expense: 1926382.00
DRMA income_statement (quarterly, 2026-03-31) — +Total Revenue: 0.00
DRMA balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 318331.00
DRMA balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 81494203.00
DRMA income_statement (quarterly, 2026-03-31) — Basic Average Shares: 3858921.00
DRMA income_statement (quarterly, 2026-03-31) — Basic EPS: -0.48
DRMA cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 7521978.00
DRMA balance_sheet (quarterly, 2026-03-31) — Capital Stock: 402.00
DRMA balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 6945282.00
DRMA balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 6945282.00
DRMA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 1903022.00
DRMA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -2479718.00
DRMA cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -51128.00
DRMA cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -445640.00
DRMA cash_flow (quarterly, 2026-03-31) — Change In Inventory: -93091.00
DRMA cash_flow (quarterly, 2026-03-31) — Change In Payable: -51128.00
DRMA cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -496768.00
DRMA cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -85431.00
DRMA cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -675290.00
DRMA cash_flow (quarterly, 2026-03-31) — Changes In Cash: -576696.00
DRMA balance_sheet (quarterly, 2026-03-31) — Common Stock: 402.00
DRMA balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 6413003.00
DRMA cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 1994374.00
DRMA balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 449537.00
DRMA balance_sheet (quarterly, 2026-03-31) — Current Assets: 7465652.00
DRMA balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 1052649.00
DRMA income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 3858921.00
DRMA income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.48
DRMA income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -1847706.00
DRMA income_statement (quarterly, 2026-03-31) — EBIT: -1926382.00
DRMA income_statement (quarterly, 2026-03-31) — EBITDA: -1926382.00
DRMA cash_flow (quarterly, 2026-03-31) — End Cash Position: 6945282.00
DRMA cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 1903022.00
DRMA cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -2479718.00
DRMA income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 1336325.00
DRMA income_statement (quarterly, 2026-03-31) — Interest Income: 78676.00
DRMA income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 78676.00
DRMA balance_sheet (quarterly, 2026-03-31) — Inventory: 93091.00
DRMA balance_sheet (quarterly, 2026-03-31) — Invested Capital: 6413003.00
DRMA cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 1994374.00
DRMA cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 1994374.00
DRMA income_statement (quarterly, 2026-03-31) — Net Income: -1847706.00
DRMA income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -1847706.00
DRMA income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -1847706.00
DRMA income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -1847706.00
DRMA income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -1847706.00
DRMA cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -1847706.00
DRMA income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -1847706.00
DRMA income_statement (quarterly, 2026-03-31) — Net Interest Income: 78676.00
DRMA income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 78676.00
DRMA cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -91352.00
DRMA balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 6413003.00
DRMA income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -1926382.00
DRMA income_statement (quarterly, 2026-03-31) — Normalized Income: -1847706.00
DRMA cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -2479718.00
DRMA income_statement (quarterly, 2026-03-31) — Operating Income: -1926382.00
DRMA income_statement (quarterly, 2026-03-31) — Operating Revenue: 0.00
DRMA balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 4022143.00
DRMA income_statement (quarterly, 2026-03-31) — Other Gand A: 1011796.00
DRMA balance_sheet (quarterly, 2026-03-31) — Payables: 318331.00
DRMA balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 767868.00
DRMA balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 284781.00
DRMA balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 427279.00
DRMA income_statement (quarterly, 2026-03-31) — Pretax Income: -1847706.00
DRMA cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 0.00
DRMA balance_sheet (quarterly, 2026-03-31) — Raw Materials: 93091.00
DRMA income_statement (quarterly, 2026-03-31) — Research And Development: 383724.00
DRMA balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -75081602.00
DRMA income_statement (quarterly, 2026-03-31) — Salaries And Wages: 324529.00
DRMA income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 206333.00
DRMA income_statement (quarterly, 2026-03-31) — Selling General And Administration: 1542658.00
DRMA balance_sheet (quarterly, 2026-03-31) — Share Issued: 4022143.00
DRMA cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 43278.00
DRMA balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 6413003.00
DRMA balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 6413003.00
DRMA income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
DRMA income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
DRMA balance_sheet (quarterly, 2026-03-31) — Total Assets: 7465652.00
DRMA balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 6413003.00
DRMA balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 6413003.00
DRMA income_statement (quarterly, 2026-03-31) — Total Expenses: 1926382.00
DRMA balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 1052649.00
DRMA balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 0.00
DRMA balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 0.00
DRMA income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -1926382.00
DRMA balance_sheet (quarterly, 2026-03-31) — Working Capital: 6413003.00
DRO.AX balance_sheet (annual, 2021-12-31) — Current Debt: 56584.00
DRO.AX balance_sheet (annual, 2021-12-31) — Current Deferred Revenue: 1566894.00
DRO.AX balance_sheet (annual, 2021-12-31) — Foreign Currency Translation Adjustments: 124208.00
DRO.AX balance_sheet (annual, 2021-12-31) — Goodwill And Other Intangible Assets: 38222.00
DRO.AX cash_flow (annual, 2021-12-31) — Interest Paid Cff: 35827.00
DRO.AX balance_sheet (annual, 2021-12-31) — Long Term Capital Lease Obligation: 38802.00
DRO.AX balance_sheet (annual, 2021-12-31) — Long Term Debt And Capital Lease Obligation: 38802.00
DRO.AX balance_sheet (annual, 2021-12-31) — Other Current Borrowings: 56584.00
DRO.AX balance_sheet (annual, 2021-12-31) — Other Intangible Assets: 38222.00
DRO.AX income_statement (annual, 2021-12-31) — Other Operating Expenses: 4725156.00
DRO.AX balance_sheet (annual, 2021-12-31) — Other Short Term Investments: 75000.00
DRO.AX balance_sheet (annual, 2021-12-31) — Work In Process: 4792511.00
DRO.AX income_statement (annual, 2022-12-31) — +Operating Expense: 16041290.00
DRO.AX income_statement (annual, 2022-12-31) — +Total Revenue: 16806723.00
DRO.AX balance_sheet (annual, 2022-12-31) — Accounts Payable: 564231.00
DRO.AX balance_sheet (annual, 2022-12-31) — Accounts Receivable: 6847705.00
DRO.AX balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -1283284.00
DRO.AX income_statement (annual, 2022-12-31) — Amortization: 13674.00
DRO.AX income_statement (annual, 2022-12-31) — Amortization Of Intangibles Income Statement: 13674.00
DRO.AX income_statement (annual, 2022-12-31) — Basic Average Shares: 429980471.00
DRO.AX income_statement (annual, 2022-12-31) — Basic EPS: 0.00
DRO.AX cash_flow (annual, 2022-12-31) — Beginning Cash Position: 9419235.00
DRO.AX cash_flow (annual, 2022-12-31) — Capital Expenditure: -832175.00
DRO.AX balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 526045.00
DRO.AX balance_sheet (annual, 2022-12-31) — Capital Stock: 40535156.00
DRO.AX balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 10143861.00
DRO.AX balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 10218861.00
DRO.AX balance_sheet (annual, 2022-12-31) — Cash Equivalents: 853032.00
DRO.AX balance_sheet (annual, 2022-12-31) — Cash Financial: 9290829.00
DRO.AX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 3077866.00
DRO.AX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -832175.00
DRO.AX cash_flow (annual, 2022-12-31) — Cash Flowsfromusedin Operating Activities Direct: -1765945.00
DRO.AX cash_flow (annual, 2022-12-31) — Changes In Cash: 479746.00
DRO.AX cash_flow (annual, 2022-12-31) — Classesof Cash Payments: -15374532.00
DRO.AX cash_flow (annual, 2022-12-31) — Classesof Cash Receiptsfrom Operating Activities: 13608587.00
DRO.AX balance_sheet (annual, 2022-12-31) — Common Stock: 40535156.00
DRO.AX balance_sheet (annual, 2022-12-31) — Common Stock Equity: 18999403.00
DRO.AX cash_flow (annual, 2022-12-31) — Common Stock Issuance: 3700000.00
DRO.AX income_statement (annual, 2022-12-31) — Cost Of Revenue: 4976034.00
DRO.AX balance_sheet (annual, 2022-12-31) — Current Assets: 22268925.00
DRO.AX balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 526045.00
DRO.AX balance_sheet (annual, 2022-12-31) — Current Debt: 70052.00
DRO.AX balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 596097.00
DRO.AX balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 4555326.00
DRO.AX balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 4555326.00
DRO.AX balance_sheet (annual, 2022-12-31) — Current Liabilities: 6142889.00
DRO.AX income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 930157.00
DRO.AX income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 930157.00
DRO.AX income_statement (annual, 2022-12-31) — Depreciation Income Statement: 916483.00
DRO.AX income_statement (annual, 2022-12-31) — Diluted Average Shares: 429980471.00
DRO.AX income_statement (annual, 2022-12-31) — Diluted EPS: 0.00
DRO.AX income_statement (annual, 2022-12-31) — EBIT: -4210601.00
DRO.AX income_statement (annual, 2022-12-31) — EBITDA: -3280444.00
DRO.AX cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: 244880.00
DRO.AX balance_sheet (annual, 2022-12-31) — Employee Benefits: 64760.00
DRO.AX cash_flow (annual, 2022-12-31) — End Cash Position: 10143861.00
DRO.AX cash_flow (annual, 2022-12-31) — Financing Cash Flow: 3077866.00
DRO.AX balance_sheet (annual, 2022-12-31) — Finished Goods: 1329682.00
DRO.AX cash_flow (annual, 2022-12-31) — Free Cash Flow: -2598120.00
DRO.AX balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: 5088141.00
DRO.AX income_statement (annual, 2022-12-31) — General And Administrative Expense: 3701525.00
DRO.AX balance_sheet (annual, 2022-12-31) — Gross PPE: 4178511.00
DRO.AX income_statement (annual, 2022-12-31) — Gross Profit: 11830689.00
DRO.AX income_statement (annual, 2022-12-31) — Interest Income: 19098.00
DRO.AX income_statement (annual, 2022-12-31) — Interest Income Non Operating: 19098.00
DRO.AX balance_sheet (annual, 2022-12-31) — Inventory: 3733416.00
DRO.AX balance_sheet (annual, 2022-12-31) — Invested Capital: 19069455.00
DRO.AX cash_flow (annual, 2022-12-31) — Investing Cash Flow: -832175.00
DRO.AX balance_sheet (annual, 2022-12-31) — Investments And Advances: 42900.00
DRO.AX cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 3700000.00
DRO.AX balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 3643900.00
DRO.AX cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 3700000.00
DRO.AX income_statement (annual, 2022-12-31) — Net Income: -949301.00
DRO.AX income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -949301.00
DRO.AX income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -949301.00
DRO.AX income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -949301.00
DRO.AX income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -949301.00
DRO.AX income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -949301.00
DRO.AX income_statement (annual, 2022-12-31) — Net Interest Income: 19098.00
DRO.AX income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 19098.00
DRO.AX cash_flow (annual, 2022-12-31) — Net Other Financing Charges: -1263365.00
DRO.AX balance_sheet (annual, 2022-12-31) — Net PPE: 2895227.00
DRO.AX cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -832175.00
DRO.AX balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 18999403.00
DRO.AX balance_sheet (annual, 2022-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 64760.00
DRO.AX income_statement (annual, 2022-12-31) — Normalized EBITDA: -3280444.00
DRO.AX income_statement (annual, 2022-12-31) — Normalized Income: -949301.00
DRO.AX income_statement (annual, 2022-12-31) — Operating Income: -4210601.00
DRO.AX income_statement (annual, 2022-12-31) — Operating Revenue: 16806723.00
DRO.AX balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 429980471.00
DRO.AX cash_flow (annual, 2022-12-31) — Other Cash Paymentsfrom Operating Activities: 2090914.00
DRO.AX cash_flow (annual, 2022-12-31) — Other Cash Receiptsfrom Operating Activities: 75548.00
DRO.AX balance_sheet (annual, 2022-12-31) — Other Current Borrowings: 70052.00
DRO.AX balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: 5088141.00
DRO.AX income_statement (annual, 2022-12-31) — Other Gand A: 1550890.00
DRO.AX income_statement (annual, 2022-12-31) — Other Income Expense: 332514.00
DRO.AX balance_sheet (annual, 2022-12-31) — Other Investments: 42900.00
DRO.AX income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: 332514.00
DRO.AX income_statement (annual, 2022-12-31) — Other Operating Expenses: 4793504.00
DRO.AX balance_sheet (annual, 2022-12-31) — Other Properties: 534611.00
DRO.AX balance_sheet (annual, 2022-12-31) — Other Receivables: 31478.00
DRO.AX balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 75000.00
DRO.AX balance_sheet (annual, 2022-12-31) — Payables: 564231.00
DRO.AX balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 564231.00
DRO.AX cash_flow (annual, 2022-12-31) — Paymentsto Suppliersfor Goodsand Services: -17465446.00
DRO.AX balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 427235.00
DRO.AX balance_sheet (annual, 2022-12-31) — Prepaid Assets: 1437465.00
DRO.AX income_statement (annual, 2022-12-31) — Pretax Income: -2928832.00
DRO.AX cash_flow (annual, 2022-12-31) — Purchase Of PPE: -832175.00
DRO.AX balance_sheet (annual, 2022-12-31) — Raw Materials: 2403734.00
DRO.AX cash_flow (annual, 2022-12-31) — Receiptsfrom Customers: 13533039.00
DRO.AX balance_sheet (annual, 2022-12-31) — Receivables: 6879183.00
DRO.AX income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 4976034.00
DRO.AX income_statement (annual, 2022-12-31) — Reconciled Depreciation: 930157.00
DRO.AX income_statement (annual, 2022-12-31) — Research And Development: 6616104.00
DRO.AX balance_sheet (annual, 2022-12-31) — Retained Earnings: -26623894.00
DRO.AX income_statement (annual, 2022-12-31) — Salaries And Wages: 2150635.00
DRO.AX income_statement (annual, 2022-12-31) — Selling General And Administration: 3701525.00
DRO.AX balance_sheet (annual, 2022-12-31) — Share Issued: 429980471.00
DRO.AX balance_sheet (annual, 2022-12-31) — Stockholders Equity: 18999403.00
DRO.AX balance_sheet (annual, 2022-12-31) — Tangible Book Value: 18999403.00
DRO.AX income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
DRO.AX income_statement (annual, 2022-12-31) — Tax Provision: -1979531.00
DRO.AX income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.30
DRO.AX balance_sheet (annual, 2022-12-31) — Total Assets: 25207052.00
DRO.AX balance_sheet (annual, 2022-12-31) — Total Capitalization: 18999403.00
DRO.AX balance_sheet (annual, 2022-12-31) — Total Debt: 596097.00
DRO.AX balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 18999403.00
DRO.AX balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 6207649.00
DRO.AX balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 2938127.00
DRO.AX balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 64760.00
DRO.AX balance_sheet (annual, 2022-12-31) — Working Capital: 16126036.00
DRO.AX income_statement (annual, 2023-12-31) — +Operating Expense: 37910251.00
DRO.AX income_statement (annual, 2023-12-31) — +Total Revenue: 54088928.00
DRO.AX balance_sheet (annual, 2023-12-31) — Accounts Payable: 3488243.00
DRO.AX balance_sheet (annual, 2023-12-31) — Accounts Receivable: 2238938.00
DRO.AX balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -1866704.00
DRO.AX income_statement (annual, 2023-12-31) — Amortization: 14579.00
DRO.AX income_statement (annual, 2023-12-31) — Amortization Of Intangibles Income Statement: 14579.00
DRO.AX income_statement (annual, 2023-12-31) — Basic Average Shares: 464029449.00
DRO.AX income_statement (annual, 2023-12-31) — Basic EPS: 0.02
DRO.AX cash_flow (annual, 2023-12-31) — Beginning Cash Position: 10143861.00
DRO.AX cash_flow (annual, 2023-12-31) — Capital Expenditure: -2926014.00
DRO.AX balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 2625404.00
DRO.AX balance_sheet (annual, 2023-12-31) — Capital Stock: 80377638.00
DRO.AX balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 56696346.00
DRO.AX balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 56771346.00
DRO.AX balance_sheet (annual, 2023-12-31) — Cash Equivalents: 20829391.00
DRO.AX balance_sheet (annual, 2023-12-31) — Cash Financial: 35866955.00
DRO.AX cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 39109757.00
DRO.AX cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -1951684.00
DRO.AX cash_flow (annual, 2023-12-31) — Cash Flowsfromusedin Operating Activities Direct: 9482476.00
DRO.AX cash_flow (annual, 2023-12-31) — Changes In Cash: 46640549.00
DRO.AX cash_flow (annual, 2023-12-31) — Classesof Cash Payments: -59739020.00
DRO.AX cash_flow (annual, 2023-12-31) — Classesof Cash Receiptsfrom Operating Activities: 70921059.00
DRO.AX balance_sheet (annual, 2023-12-31) — Common Stock: 80377638.00
DRO.AX balance_sheet (annual, 2023-12-31) — Common Stock Equity: 74511293.00
DRO.AX cash_flow (annual, 2023-12-31) — Common Stock Issuance: 41941563.00
DRO.AX cash_flow (annual, 2023-12-31) — Common Stock Payments: -2247081.00
DRO.AX income_statement (annual, 2023-12-31) — Cost Of Revenue: 15137250.00
DRO.AX balance_sheet (annual, 2023-12-31) — Current Assets: 84644562.00
DRO.AX balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 451435.00
DRO.AX balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 451435.00
DRO.AX balance_sheet (annual, 2023-12-31) — Current Deferred Assets: 348994.00
DRO.AX balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 15694674.00
DRO.AX balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 15324244.00
DRO.AX balance_sheet (annual, 2023-12-31) — Current Deferred Taxes Assets: 348994.00
DRO.AX balance_sheet (annual, 2023-12-31) — Current Deferred Taxes Liabilities: 370430.00
DRO.AX balance_sheet (annual, 2023-12-31) — Current Liabilities: 20225932.00
DRO.AX income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 1522845.00
DRO.AX income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 1522845.00
DRO.AX income_statement (annual, 2023-12-31) — Depreciation Income Statement: 1508266.00
DRO.AX income_statement (annual, 2023-12-31) — Diluted Average Shares: 464029449.00
DRO.AX income_statement (annual, 2023-12-31) — Diluted EPS: 0.02
DRO.AX income_statement (annual, 2023-12-31) — EBIT: 1041427.00
DRO.AX income_statement (annual, 2023-12-31) — EBITDA: 2564272.00
DRO.AX cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -88064.00
DRO.AX balance_sheet (annual, 2023-12-31) — Employee Benefits: 140711.00
DRO.AX cash_flow (annual, 2023-12-31) — End Cash Position: 56696346.00
DRO.AX cash_flow (annual, 2023-12-31) — Financing Cash Flow: 39109757.00
DRO.AX balance_sheet (annual, 2023-12-31) — Finished Goods: 8047022.00
DRO.AX cash_flow (annual, 2023-12-31) — Free Cash Flow: 6556462.00
DRO.AX balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: 5473844.00